



***Corporate Governance prize awarded by AGEFI:  
Onxeo receives “Silver Governance”  
for the second consecutive year***

**Paris (France) and Copenhagen (Denmark), September 17, 2015** – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has been awarded for the second consecutive year the “Silver Governance” in the small and midcap companies category at the Twelfth Annual Corporate Governance Awards held by the French financial magazine AGEFI on September 16, 2015.

The Corporate Governance Prizes reward listed companies with the best corporate governance practices, in particular as regards the composition of the companies’ Board of Directors, the transparency of communication, the functioning of corporate bodies, social responsibility, and risk management. The awards are based on the results of a survey of finance industry professionals. The methodology is validated by a steering committee which identifies the companies’ good practices based on data provided in the annual reports and reference documents.

*“We are very happy to, once again, be awarded with this prize which reflects the excellence of our governance and our efforts to implement the best corporate processes. These are key in strengthening our shareholders’ and the market’s confidence in Onxeo. Therefore, we will continue to ensure that we are up to the highest standards in these fields”,* commented Patrick Langlois, Chairman of the Board of Directors of Onxeo.

**About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to “make the difference”. The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

***Key orphan oncology products at the advanced development stage are:***

Livatag<sup>®</sup> (doxorubicin Transdrug<sup>™</sup>): Phase III in hepatocellular carcinoma

Validive<sup>®</sup> (clonidine Lauriad<sup>®</sup>): Phase II in severe oral mucositis: Positive final results

Beleodaq<sup>®</sup> (belinostat): registered in the US in 2<sup>nd</sup> line treatment of peripheral T-cell lymphoma

*For more information, visit the website [www.onxeo.com](http://www.onxeo.com)*

**To receive our press releases and newsletters, please register on: <http://www.onxeo.com/en/newsletter/>  
Follow us on twitter @Onxeo\_**

**Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo*

*is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website ([www.onxeo.com](http://www.onxeo.com)).*

**Contacts :**

Judith Greciet, CEO  
j.greciet@onxeo.com  
Nicolas Fellmann, CFO  
n.fellmann@onxeo.com  
+33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie  
onxeo@alizerp.com  
+33 6 64 18 99 59 / +33 6 47 38 90 04